Quantcast

Latest Cebix Incorporated Stories

2011-06-24 16:00:00

LA JOLLA, Calif., June 24, 2011 /PRNewswire/ -- Cebix Incorporated announced today that preclinical data for its long-acting form of C-peptide, Ersatta(TM) (CBX129801), demonstrated a half-life of three days as compared to one hour for native C-peptide. Ersatta halted the impairment in nerve conduction velocity, a measure of the rate at which electrical signals travel through the nerves, in an animal model of diabetic peripheral neuropathy. Additionally, clinical data showed that native...

2011-06-16 07:00:00

LA JOLLA, Calif., June 16, 2011 /PRNewswire/ -- Cebix Incorporated announced today it is advancing the development of modified C-peptide for the treatment of complications of diabetes. The biopharmaceutical company has initiated a Phase 1b clinical trial to evaluate Ersatta(TM), its proprietary long-acting form of C-peptide, in patients with type 1 diabetes who, because of their disease, lack this endogenous peptide. Following the successful completion of this study, the company is...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related